

1645

# FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP  
600 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TEXAS 78701-3271  
WWW.FULBRIGHT.COM

STEVEN L. HIGHLANDER  
PARTNER  
SHIGHLANDER@FULBRIGHT.COM


DIRECT DIAL: (512) 536-3184  
TELEPHONE: (512) 474-5201  
FACSIMILE: (512) 536-4598

RECEIVED

March 25, 2003

APR 01 2003

TECH CENTER 1600/2900

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: BOX DD, Commissioner for Patents, Washington, DC 20231, on the date below:	
March 25, 2003	
Date	
	Steven L. Highlander

## BOX DD

Commissioner for Patents  
Washington, DC 20231

RE: *U.S. Patent Application No. 09/718,355 entitled "LOCI FOR IDIOPATHIC GENERALIZED EPILEPSY, MUTATIONS THEREOF AND METHOD USING SAME TO ASSESS, DIAGNOSE, PROGNOSIS OR TREAT EPILEPSY" – Guy A. Rouleau et al.*  
Our reference: GOUD:023US  
Client reference: 760/13180.18


Sir:

Enclosed for filing in the above-referenced patent application is a Supplemental Information Disclosure Statement, Form PTO-1449, and references B1, C1-C5.

No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/GOUD:023US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

  
Steven L. Highlander  
Reg. No. 37,642

SLH/cmb  
Encl.: as noted  
25271598.1



**PATENT**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:  
Guy A. Rouleau *et al.*

Serial No.: 09/718,355

Filed: November 24, 2000

For: LOCI FOR IDIOPATHIC GENERALIZED  
EPILEPSY, MUTATIONS THEREOF  
AND METHOD USING SAME TO  
ASSESS, DIAGNOSE, PROGNOSIS OR  
TREAT EPILEPSY

Group Art Unit: 1645


Examiner: Unknown

Atty. Dkt. No.: GOUD-0231US

**RECEIVED**

APR 01 2003

TECH CENTER 1600/2900

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Box DD, Commissioner for Patents, Washington, DC 20231, on the date below:	
March 25, 2003	
Date	Steven L. Highlander

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

**BOX DD**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.


In accordance with 37 C.F.R. §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be

construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/GOUD:023US.

Applicants respectfully request that the listed documents be made of record in the present case.


Respectfully submitted,



Steven L. Highlander  
Reg. No. 37,642  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201

Date: March 25, 2003



Form PTO-1449 (modified)		Atty. Docket No. <b>GOUD:023US</b>	Serial No. <b>09/718,355</b>
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant <b>Guy A. Rouleau <i>et al.</i></b>	
		Filing Date: <b>November 24, 2000</b>	Group: <b>1645</b>
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

**U.S. Patent Documents**

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

**Foreign Patent Documents**

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	WO 99/21875	5/6/99	PCT			

**Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
	C1	Baulac <i>et al.</i> , "A second locus for familial generalized epilepsy with febrile seizures plus maps to chromosome 2q21-q33," <i>Am. J. Hum. Genet.</i> , 65:1078-1085, 1999.
	C2	Malo <i>et al.</i> , "Localization of a putative human brain sodium channel gene (SCN1A) to chromosome band 2q24," <i>Cytogenet. Cell Genet.</i> , 67:178-186, 1994.
	C3	Malo <i>et al.</i> , "Targeted gene walking by low stringency polymerase chain reaction: assignment of a putative human brain sodium channel gene (SCN3A) to chromosome 2q24-31," <i>Proc. Natl. Acad. Sci., USA</i> , 91:2975-2979, 1994.
	C4	Moulard <i>et al.</i> , "Identification of a new locus for generalized epilepsy with febrile seizures plus (GEFS+) on chromosome 2q24-q33," <i>Am. J. Hum. Genet.</i> , 65:1396-1400, 1999.
	C5	Plummer and Meisler, "Evolution and diversity of mammalian sodium channel genes," <i>Genomics</i> , 57:323-331, 1999.

25271542.1

**EXAMINER:****DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.